General Information of Drug (ID: DMBER0Q)

Drug Name
Hu5F9-G4 Drug Info
Indication
Disease Entry ICD 11 Status REF
Myelodysplastic syndrome 2A37 Phase 3 [1]
B-cell non-hodgkin lymphoma 2B33.5 Phase 1/2 [2]
Colorectal cancer 2B91.Z Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Acute myeloid leukaemia 2A60 Phase 1 [3]
Cross-matching ID
TTD Drug ID
DMBER0Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Evorpacept DMJTX7Q Gastric cancer 2B72 Phase 2/3 [4]
PF-07901801 DMEVYHR Diffuse large B-cell lymphoma 2A81 Phase 2 [5]
ALX148 DMGQX0U Myelodysplastic syndrome 2A37 Phase 1/2 [2]
DSP-107 DM8K0PR Solid tumour/cancer 2A00-2F9Z Phase 1/2 [6]
AO-176 DMXU98C Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
TG-1801 DM3K4FY B-cell lymphoma 2A86 Phase 1 [8]
SL-172154 DMN3D72 Ovarian cancer 2C73 Phase 1 [9]
TTI-621 DMDNPAV Haematological malignancy 2B33.Y Phase 1 [10]
TTI-622 DMOCQ4K Lymphoma 2A80-2A86 Phase 1 [11]
IBI188 DMXUJ1P Myelodysplastic syndrome 2A37 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen CD47 (CD47) TT28S46 CD47_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04313881) Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
5 ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
6 Clinical pipeline report, company report or official report of KAHR Medical.
7 Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
8 Clinical pipeline report, company report or official report of TG Theraputics.
9 Clinical pipeline report, company report or official report of Shattuck Labs.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Clinical pipeline report, company report or official report of Trillium Therapeutics.
12 Clinical pipeline report, company report or official report of Innovent Biologics.